This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Sponsored by Vertex Pharmaceuticals Incorporated

About this trial

Last updated 2 years ago

Study ID

VX21-CTX001-141

Status

Recruiting

Type

Interventional

Phase

Phase 3

Placebo

No

Accepting

18-75 Years
2 to 11 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 3 years ago

What is this trial about?

This is a single-dose, open-label study in pediatric participants with TDT. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).

What are the Participation Requirements?

Key Inclusion Criteria:

- Diagnosis of TDT as defined by:

- Documented homozygous or compound heterozygous β-thalassemia including
β-thalassemia/hemoglobin E (HbE). Participants can be enrolled based on
historical data, but a confirmation of the genotype using the study central
laboratory will be required before busulfan conditioning

- History of at least 100 mL/kilograms (kg)/year of packed RBC transfusions in the
prior 24 months before signing of consent (or the last rescreening for patients
going through repeat screening) or, for participants initiating transfusion
therapy <24 months before signing of consent, requirement for packed RBC
transfusion at least every 3 to 4 weeks for ≥6 months

- Eligible for autologous stem cell transplant as per investigator's judgment.

Key Exclusion Criteria:

- A willing and healthy 10/10 human leukocyte antigen (HLA)-matched related donor is
available per investigator's judgement

- Prior hematopoietic stem cell transplant (HSCT)

- Participants with associated α-thalassemia and >1 alpha deletion, or alpha
multiplications

- Participants with sickle cell β-thalassemia variant

- Clinically significant and active bacterial, viral, fungal, or parasitic infection as
determined by the investigator

Other protocol defined Inclusion/Exclusion criteria may apply.

Locations

Location

Status

Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting